Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin-Structure Infection

Duke Clinical Research Institute, Durham, North Carolina 27715, USA.
Clinical Infectious Diseases (Impact Factor: 9.42). 09/2010; 51(6):641-50. DOI: 10.1086/655827
Source: PubMed

ABSTRACT Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of complicated skin and skin-structure infection (cSSSI). Increasing antimicrobial resistance in cSSSI has led to a need for new safe and effective therapies. Ceftaroline was evaluated as treatment for cSSSI in 2 identical phase 3 clinical trials, the pooled analysis of which is presented here. The primary objective of each trial was to determine the noninferiority of the clinical cure rate achieved with ceftaroline monotherapy, compared with that achieved with vancomycin plus aztreonam combination therapy, in the clinically evaluable (CE) and modified intent-to-treat (MITT) patient populations.
Adult patients with cSSSI requiring intravenous therapy received ceftaroline (600 mg every 12 h) or vancomycin plus aztreonam (1 g each every 12 h) for 5-14 days.
Of 1378 patients enrolled in both trials, 693 received ceftaroline and 685 received vancomycin plus aztreonam. Baseline characteristics of the treatment groups were comparable. Clinical cure rates were similar for ceftaroline and vancomycin plus aztreonam in the CE (91.6% vs 92.7%) and MITT (85.9% vs 85.5%) populations, respectively, as well as in patients infected with MRSA (93.4% vs 94.3%). The rates of adverse events, discontinuations because of an adverse event, serious adverse events, and death also were similar between treatment groups.
Ceftaroline achieved high clinical cure rates, was efficacious against cSSSI caused by MRSA and other common cSSSI pathogens, and was well tolerated, with a safety profile consistent with the cephalosporin class. Ceftaroline has the potential to provide a monotherapy alternative for the treatment of cSSSI. identifiers: NCT00424190 for CANVAS 1 and NCT00423657 for CANVAS 2.

Download full-text


Available from: Tanya O'Neal, Jun 24, 2015
  • Source
    Drug Development - A Case Study Based Insight into Modern Strategies, 12/2011; , ISBN: 978-953-307-257-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: The methodology for an economic assessment of an aircraft reliability assurance warranty program (RAWP) presented in this work allows maintenance costs to be projected for the life of a program with and without RAWP. The methodology makes use of relationships outlined in MIL-HDBK-189 and combines them with repair cost estimation to present a unique picture of how maintenance costs can change over product life. This specifically allows the value of a RAWP program to be assessed and meaningful decisions made as to its merits
    Reliability and Maintainability Symposium, 1991. Proceedings., Annual; 03/1991
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary form only given. It is pointed out that, to develop a meaningful computerized concurrent engineering environment for the design of electronic equipment, the tools to be incorporated must be assessed as to their appropriateness and accuracy. To be useful, the methods employed by the software tools developed must be based on a scientific foundation. A general evaluation of many of the R&M software tools and associated techniques presently being utilized suggests that US electronics industries that use such software may be in trouble. The problem is that many of the R&M techniques that have been computerized are not appropriate for design and not based on any scientific foundation. It is thus concluded that the use of these tools for the development of new cost-effective and timely products will further decrease US competitiveness in the global market
    Semiconductor Thermal Measurement and Management Symposium, 1991. SEMI-THERM VII. Proceedings., Seventh Annual IEEE; 03/1991